Conclusion of the transaction is now expected to occur in the third quarter of this year, subject to satisfaction of customary closing conditions, including regulatory approvals.
Vicuron has two new drug applications submitted to the FDA for its two lead products, dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections, and anidulafungin, a novel antifungal agent.
Vicuron applies a disciplined, integrated approach to anti-infective discovery for next-generation compounds in both hospital-based and community-acquired infections.